LON:DNL - Diurnal Group Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
GBX 195 0.00 (0.00 %)
(As of 05/25/2018 04:00 PM ET)
Previous CloseGBX 195
Today's RangeGBX 194 - GBX 194
52-Week RangeGBX 118 - GBX 215.80
Volume740 shs
Average Volume7,428 shs
Market Capitalization£160.17 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Diurnal Group (LON:DNL)

Diurnal Group logoDiurnal Group plc operates as a specialty pharmaceutical company. The company develops hormone therapeutics for the treatment of rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. Its product pipeline includes Infacort for use in children suffering from adrenal insufficiency; and Chronocort that is in Phase III clinical trials targeting congenital adrenal hyperplasia in adult patients. The company's early stage pipeline products comprise Native Oral Testosterone, a replacement treatment for patients suffering from hypogonadism; Rheumacor for the treatment of inflammatory diseases; and T3 modified, a modified-release preparation of T3 (levothyroxine) hormone for patients suffering from hypothyroidism; and siRNA, a short interfering RNA oligonucleotide therapy for patients suffering from adrenocorticotropin-dependent cushing's syndrome. Diurnal Group plc was incorporated in 2015 and is headquartered in Cardiff, the United Kingdom.

Receive DNL News and Ratings via Email

Sign-up to receive the latest news and ratings for DNL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
SymbolLON:DNL
CUSIPN/A
Phone+44-29-20682069

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-39.52%
Return on Assets-29.56%

Miscellaneous

EmployeesN/A
Outstanding Shares52,320,000

Diurnal Group (LON:DNL) Frequently Asked Questions

What is Diurnal Group's stock symbol?

Diurnal Group trades on the London Stock Exchange (LON) under the ticker symbol "DNL."

How were Diurnal Group's earnings last quarter?

Diurnal Group (LON:DNL) released its quarterly earnings data on Monday, March, 12th. The company reported ($12.70) EPS for the quarter. View Diurnal Group's Earnings History.

What price target have analysts set for DNL?

2 Wall Street analysts have issued 12-month price objectives for Diurnal Group's stock. Their forecasts range from GBX 178 to GBX 185. On average, they expect Diurnal Group's stock price to reach GBX 181.50 in the next year. View Analyst Ratings for Diurnal Group.

Who are some of Diurnal Group's key competitors?

Who are Diurnal Group's key executives?

Diurnal Group's management team includes the folowing people:
  • Dr. Martin Whitaker BSc, Ph.D., Chief Exec. Officer and Exec. Director
  • Prof. Richard Ross MBBS, M.D., FRCP, Chief Scientific Officer and Exec. Director
  • Mr. Richard Edward Bungay BSc, ACA, Chief Financial Officer and Director (Age 49)
  • Mr. Michael Withe, Commercial Director
  • Mr. John Porter MBBS, Ph.D., Medical Affairs Director

Has Diurnal Group been receiving favorable news coverage?

Media stories about DNL stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Diurnal Group earned a daily sentiment score of 0.18 on Accern's scale. They also assigned news coverage about the company an impact score of 44.78 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Diurnal Group?

Shares of DNL and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Diurnal Group's stock price today?

One share of DNL stock can currently be purchased for approximately GBX 195.

How big of a company is Diurnal Group?

Diurnal Group has a market capitalization of £160.17 million.

How can I contact Diurnal Group?

Diurnal Group's mailing address is Heath Park, CARDIFF, CF14 4UJ, United Kingdom. The company can be reached via phone at +44-29-20682069.


MarketBeat Community Rating for Diurnal Group (DNL)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  107 (Vote Outperform)
Underperform Votes:  66 (Vote Underperform)
Total Votes:  173
MarketBeat's community ratings are surveys of what our community members think about Diurnal Group and other stocks. Vote "Outperform" if you believe DNL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DNL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Diurnal Group (LON:DNL) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Diurnal Group in the last 12 months. Their average twelve-month price target is GBX 181.50The high price target for DNL is GBX 185 and the low price target for DNL is GBX 178. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 181.50GBX 181.50GBX 181.50GBX 173.50

Diurnal Group (LON:DNL) Consensus Price Target History

Price Target History for Diurnal Group (LON:DNL)

Diurnal Group (LON:DNL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
2/13/2018Numis SecuritiesReiterated RatingBuyGBX 185View Rating Details
6/15/2017Panmure GordonReiterated RatingBuyGBX 178View Rating Details
(Data available from 5/25/2016 forward)

Earnings

Diurnal Group (LON:DNL) Earnings History and Estimates Chart

Earnings by Quarter for Diurnal Group (LON:DNL)

Diurnal Group (LON DNL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018S1 2018GBX (12.70)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Diurnal Group (LON:DNL) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Diurnal Group (LON DNL) Insider Trading and Institutional Ownership History

Insider Trading History for Diurnal Group (LON:DNL)

Diurnal Group (LON DNL) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/5/2018John GoddardInsiderBuy10,791GBX 540£58,271.40
11/27/2017Martin WhitakerInsiderBuy3,703GBX 135£4,999.05
11/8/2017Martin WhitakerInsiderSell33,650GBX 135£45,427.50
9/7/2017John GoddardInsiderBuy10,791GBX 5£539.55
1/16/2017Alan RaymondInsiderBuy9,000GBX 110£9,900
1/13/2017Sam WilliamsInsiderBuy9,248GBX 108£9,987.84
(Data available from 1/1/2013 forward)

Headlines

Diurnal Group (LON DNL) News Headlines

Source:
DateHeadline
Appointment of CRO to support US Chronocort trials - London South East (blog)Appointment of CRO to support US Chronocort trials - London South East (blog)
www.lse.co.uk - March 13 at 5:31 PM
UPDATE: Diurnal Prepares For First Revenue As Appoints Trial PartnerUPDATE: Diurnal Prepares For First Revenue As Appoints Trial Partner
www.morningstar.co.uk - March 12 at 4:39 PM
BRIEF-Diurnal Group Says ‍HY Operating Loss Of 7.7 Mln StgBRIEF-Diurnal Group Says ‍HY Operating Loss Of 7.7 Mln Stg
www.reuters.com - March 12 at 4:39 PM
Diurnal Group (DNL) Issues  Earnings ResultsDiurnal Group (DNL) Issues Earnings Results
www.americanbankingnews.com - March 12 at 7:16 AM
Diurnal Group plc (LON:DNL): Are Analysts Bull Or Bear?Diurnal Group plc (LON:DNL): Are Analysts Bull Or Bear?
finance.yahoo.com - March 6 at 10:18 AM
Diurnal Group Granted First Alkindi And Chronocort Patents In JapanDiurnal Group Granted First Alkindi And Chronocort Patents In Japan
www.morningstar.co.uk - February 22 at 4:11 PM
Diurnal Group Signs Australia And New Zealand Therapies AgreementDiurnal Group Signs Australia And New Zealand Therapies Agreement
www.morningstar.co.uk - February 19 at 9:39 AM
Diurnal Groups (DNL) Buy Rating Reiterated at Numis SecuritiesDiurnal Group's (DNL) Buy Rating Reiterated at Numis Securities
www.americanbankingnews.com - February 19 at 12:34 AM
Diurnal Enrols Patients For Pivotal Chronocort Clinical TrialDiurnal Enrols Patients For Pivotal Chronocort Clinical Trial
www.morningstar.co.uk - February 12 at 5:10 PM
Diurnal Group PLC (DNL) Insider Acquires £58,271.40 in StockDiurnal Group PLC (DNL) Insider Acquires £58,271.40 in Stock
www.americanbankingnews.com - January 5 at 3:14 PM
Diurnal Group (DNL) Receives Buy Rating from Numis SecuritiesDiurnal Group (DNL) Receives Buy Rating from Numis Securities
www.americanbankingnews.com - December 19 at 12:38 AM
Insider Buying: Diurnal Group PLC (DNL) Insider Buys 3,703 Shares of StockInsider Buying: Diurnal Group PLC (DNL) Insider Buys 3,703 Shares of Stock
www.americanbankingnews.com - November 29 at 10:30 AM
Diurnal Group PLC (DNL) Insider Martin Whitaker Sells 33,650 SharesDiurnal Group PLC (DNL) Insider Martin Whitaker Sells 33,650 Shares
www.americanbankingnews.com - November 14 at 1:28 AM
Diurnal Group PLCs (DNL) "Buy" Rating Reiterated at Numis Securities LtdDiurnal Group PLC's (DNL) "Buy" Rating Reiterated at Numis Securities Ltd
www.americanbankingnews.com - September 10 at 10:44 PM
Insider Buying: Diurnal Group PLC (DNL) Insider Purchases 10,791 Shares of StockInsider Buying: Diurnal Group PLC (DNL) Insider Purchases 10,791 Shares of Stock
www.americanbankingnews.com - September 8 at 7:16 AM
Half Year 2017 Diurnal Group PLC Earnings Release - Time Not SuppliedHalf Year 2017 Diurnal Group PLC Earnings Release - Time Not Supplied
biz.yahoo.com - March 20 at 7:48 PM
Submission of Infacort   European PUMA Application - London South East (registration) (blog)Submission of Infacort European PUMA Application - London South East (registration) (blog)
www.lse.co.uk - December 20 at 10:44 PM
Full Year 2016 Diurnal Group PLC Earnings Release - Time Not SuppliedFull Year 2016 Diurnal Group PLC Earnings Release - Time Not Supplied
biz.yahoo.com - October 12 at 9:31 AM
Half Year 2016 Diurnal Group PLC Earnings Release - Time Not SuppliedHalf Year 2016 Diurnal Group PLC Earnings Release - Time Not Supplied
biz.yahoo.com - March 30 at 7:07 AM

SEC Filings

Diurnal Group (LON:DNL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Diurnal Group (LON DNL) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.